{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:08:47Z","timestamp":1778461727504,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Analysis of the Efficacy and Safety of Azacitidine in Maintenance Therapy for Acute Myeloid Leukemia","award":["071101546"],"award-info":[{"award-number":["071101546"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15673-4","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T02:15:37Z","timestamp":1774750537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Jun-Fang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"4","key":"15673_CR1","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/bjh.70038","volume":"207","author":"B Nachmias","year":"2025","unstructured":"Nachmias B, Haran A, Yisraeli Salman M, et al. Measurable residual disease-guided therapy in acute myeloid leukaemia: practical insights. Br J Haematol. 2025;207(4):1192\u2013212. https:\/\/doi.org\/10.1111\/bjh.70038.","journal-title":"Br J Haematol"},{"key":"15673_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/17501911.2025.2557179","author":"J Cheng","year":"2025","unstructured":"Cheng J, O\u2019connell C. Novel approaches to the use of hypomethylating agents in myeloid malignancies. Epigenomics. 2025. https:\/\/doi.org\/10.1080\/17501911.2025.2557179.","journal-title":"Epigenomics"},{"issue":"12","key":"15673_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"issue":"11","key":"15673_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"20","key":"15673_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"issue":"24","key":"15673_CR6","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.04.036.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15673_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/fon.15.326","volume":"12","author":"AH Wei","year":"2016","unstructured":"Wei AH, D\u00f6hner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III International, Randomized, Double-Blind, design of the randomized, phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016;12(3):293\u2013302. https:\/\/doi.org\/10.2217\/fon.15.326.","journal-title":"Future Oncol"},{"issue":"13","key":"15673_CR8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","volume":"133","author":"G Huls","year":"2019","unstructured":"Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133(13):1457\u201364. https:\/\/doi.org\/10.1182\/blood-2018-10-879866.","journal-title":"Blood"},{"issue":"12","key":"15673_CR9","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1080\/10428194.2020.1789630","volume":"61","author":"N Ali","year":"2020","unstructured":"Ali N, Tomlinson B, Metheny L, et al. Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leuk Lymphoma. 2020;61(12):2839\u201349. https:\/\/doi.org\/10.1080\/10428194.2020.1789630.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"15673_CR10","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, et al. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873\u201389. https:\/\/doi.org\/10.1038\/s41375-021-01218-0.","journal-title":"Leukemia"},{"issue":"1","key":"15673_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91936-7","volume":"15","author":"AP De Azambuja","year":"2025","unstructured":"De Azambuja AP, Beltrame MP, Malvezzi M, et al. Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia. Sci Rep. 2025;15(1):6942. https:\/\/doi.org\/10.1038\/s41598-025-91936-7.","journal-title":"Sci Rep"},{"issue":"1","key":"15673_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01298-6","volume":"15","author":"C Jimenez-Vicente","year":"2025","unstructured":"Jimenez-Vicente C, Cardus A, Casta\u00f1o-Diez S, et al. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer J. 2025;15(1):94. https:\/\/doi.org\/10.1038\/s41408-025-01298-6.","journal-title":"Blood Cancer J"},{"issue":"12","key":"15673_CR13","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","volume":"36","author":"NJ Short","year":"2022","unstructured":"Short NJ, Zhou S, Fu C, et al. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2022;36(12):2817\u201326. https:\/\/doi.org\/10.1038\/s41375-022-01692-0.","journal-title":"Leukemia"},{"issue":"4","key":"15673_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324. https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"issue":"12","key":"15673_CR15","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","volume":"36","author":"NJ Short","year":"2022","unstructured":"Short NJ, Fu C, Berry DA, et al. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2022;36(12):2817\u201326. https:\/\/doi.org\/10.1038\/s41375-022-01692-0.","journal-title":"Leukemia"},{"issue":"25","key":"15673_CR16","doi-asserted-by":"publisher","first-page":"00029","DOI":"10.1053\/j.seminhematol.2025.06.004","volume":"S0037-1963","author":"KJ Croese","year":"2025","unstructured":"Croese KJ, Cloos J, Tettero JM. Measurable residual disease monitoring in acute myeloid leukaemia: techniques, timing and therapeutic implications. Semin Hematol. 2025;S0037-1963(25):00029\u20130. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.004.","journal-title":"Semin Hematol"},{"issue":"11","key":"15673_CR17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1182\/blood.2021014804","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras G, Morsink LM, Othus M, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139(11):1694\u2013706. https:\/\/doi.org\/10.1182\/blood.2021014804.","journal-title":"Blood"},{"issue":"13","key":"15673_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35960","volume":"131","author":"M Boyiadzis","year":"2025","unstructured":"Boyiadzis M, Wei AH, Paiva B, et al. Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): perspectives from the MRD partnership and alliance in AML clinical treatment consortium. Cancer. 2025;131(13):e35960. https:\/\/doi.org\/10.1002\/cncr.35960.","journal-title":"Cancer"},{"key":"15673_CR19","doi-asserted-by":"publisher","unstructured":"Prognosticvalue of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine. Cancer. 2025;131(17):e70053. https:\/\/doi.org\/10.1002\/cncr.70053.","DOI":"10.1002\/cncr.70053"},{"issue":"4","key":"15673_CR20","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/ajh.26846","volume":"98","author":"A Candoni","year":"2023","unstructured":"Candoni A, Lazzarotto D, Papayannidis C, et al. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax. Am J Hematol. 2023;98(4):E80\u20133. https:\/\/doi.org\/10.1002\/ajh.26846.","journal-title":"Am J Hematol"},{"issue":"3","key":"15673_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD Dinardo","year":"2019","unstructured":"Dinardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(3):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752.","journal-title":"Blood"},{"issue":"13","key":"15673_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD Dinardo","year":"2020","unstructured":"Dinardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(13):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"issue":"3","key":"15673_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14167-z","volume":"25","author":"JF Bai","year":"2025","unstructured":"Bai JF, Wang T, Li JT, et al. Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study. BMC Cancer. 2025;25(3):990. https:\/\/doi.org\/10.1186\/s12885-025-14167-z.","journal-title":"BMC Cancer"},{"issue":"7","key":"15673_CR24","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1182\/blood.2021013404","volume":"139","author":"GJ Roboz","year":"2022","unstructured":"Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022;139(7):2145\u201355. https:\/\/doi.org\/10.1182\/blood.2021013404.","journal-title":"Blood"},{"issue":"1","key":"15673_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1182\/hematology.2021000278","volume":"2021","author":"EA Griffiths","year":"2021","unstructured":"Griffiths EA. Oral hypomethylating agents: beyond convenience in MDS. Hematol Am Soc Hematol Educ Program. 2021;2021(1):439\u201347. https:\/\/doi.org\/10.1182\/hematology.2021000278.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"15673_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659253","volume":"11","author":"N Van Gils","year":"2021","unstructured":"Van Gils N, Denkers F, Smit L. Escape from treatment; the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia. Front Oncol. 2021;11(3):659253. https:\/\/doi.org\/10.3389\/fonc.2021.659253.","journal-title":"Front Oncol"},{"issue":"9","key":"15673_CR27","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3324\/haematol.2022.281810","volume":"108","author":"J Senapati","year":"2023","unstructured":"Senapati J, Kadia TM, Ravandi F. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica. 2023;108(9):2289\u2013304. https:\/\/doi.org\/10.3324\/haematol.2022.281810.","journal-title":"Haematologica"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15673-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15673-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15673-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:22:30Z","timestamp":1778458950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15673-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15673"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15673-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Center for Ethics in the First Hospital of Lanzhou University. Written informed consent was obtained from patient for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"592"}}